An anti-CD44 antibody does not enhance engraftment of DLA-identical marrow after low-dose total body irradiation.
暂无分享,去创建一个
H. Deeg | B. Sandmaier | E. Bryant | R. Storb | T. Graham | Y. Liu | F. Schuening | K. Seidel | E. Santos
[1] B. Sandmaier,et al. An antibody to CD44 enhances hematopoiesis in long-term marrow cultures. , 1996, Experimental hematology.
[2] B. Sandmaier,et al. Mechanisms of enhancement of natural killer activity by an antibody to CD44: increase in conjugate formation and release of tumor necrosis factor alpha. , 1995, Cellular immunology.
[3] H. Deeg,et al. DLA-identical marrow grafts after low-dose total-body irradiation. Addition of viable donor peripheral blood mononuclear cells does not enhance engraftment. , 1995, Transplantation.
[4] H. Deeg,et al. DLA-identical bone marrow grafts after low-dose total body irradiation: the effect of canine recombinant hematopoietic growth factors. , 1994, Blood.
[5] E. Bryant,et al. USE OF (CA)n POLYMORPHISMS TO DETERMINE THE ORIGIN OF BLOOD CELLS AFTER ALLOGENEIC CANINE MARROW GRAFTING , 1994, Transplantation.
[6] B. Sandmaier,et al. 'Resistance' to unrelated, DLA-nonidentical canine marrow grafts is unrestricted by the major histocompatibility complex. , 1994, Experimental hematology.
[7] R. Storb,et al. A simple restriction fragment-length polymorphism assay for MHC class II gene testing of dog families. , 1994, Transplantation.
[8] H. Deeg,et al. Marrow toxicity of fractionated vs. single dose total body irradiation is identical in a canine model. , 1993, International journal of radiation oncology, biology, physics.
[9] B. Sandmaier,et al. Enhancement of natural killer activity by an antibody to CD44. , 1993, Journal of immunology.
[10] R. Storb,et al. An antibody that facilitates hematopoietic engraftment recognizes CD44. , 1990, Blood.
[11] I. Stamenkovic,et al. CD44 is the principal cell surface receptor for hyaluronate , 1990, Cell.
[12] M. Pepe,et al. Comparison of fractionated to single-dose total body irradiation in conditioning canine littermates for DLA-identical marrow grafts. , 1989, Blood.
[13] H. Deeg,et al. FAILURE OF ANTITHYMOCYTE SERUM POSTGRAFTING TO OVERCOME “RESISTANCE” TO DLANONIDENTICAL CANINE MARROW GRAFTS1 , 1988, Transplantation.
[14] H. Deeg,et al. FACILITATION OF ENGRAFTMENT OF DLA‐NONIDENTICAL MARROW BY TREATMENT OF RECIPIENTS WITH MONOCLONAL ANTIBODY DIRECTED AGAINST MARROW CELLS SURVIVING RADIATION , 1987, Transplantation.
[15] H. Deeg,et al. JOINT REPORT OF THE THIRD INTERNATIONAL WORKSHOP ON CANINE IMMUNOGENETICS: II. ANALYSIS OF THE SEROLOGICAL TYPING OF CELLS , 1987, Transplantation.
[16] H. Deeg,et al. FAILURE OF ALLOGENEIC CANINE MARROW GRAFTS AFTER TOTAL‐BODY IRRADIATION: ALLOGENEIC “RESISTANCE” VERSUS TRANSFUSION‐INDUCED SENSITIZATION , 1986, Transplantation.
[17] H. Deeg,et al. Characterization of host cells involved in resistance to marrow grafts in dogs transplanted from unrelated DLA-nonidentical donors. , 1986, Blood.
[18] H. Deeg,et al. Joint report of the Third International Workshop on Canine Immunogenetics. I. Analysis of homozygous typing cells. , 1986, Transplantation.
[19] H. Deeg,et al. CYCLOSPORIN A AND METHOTREXATE IN CANINE MARROW TRANSPLANTATION: ENGRAFTMENT, GRAFT‐VERSUS-HOST DISEASE, AND INDUCTION OF TOLERANCE , 1982, Transplantation.
[20] H. Deeg,et al. Cyclosporin-A: effect on marrow engraftment and graft-versus-host disease in dogs. , 1981, Transplantation proceedings.
[21] R. Storb,et al. HEMOPOIETIC GRAFTS BETWEEN DLA‐IDENTICAL CANINE LITTERMATES FOLLOWING DIMETHYL MYLERAN: EVIDENCE FOR RESISTANCE TO GRAFTS NOT ASSOCIATED WITH DLA AND ABROGATED BY ANTITHYMOCYTE SERUM , 1977, Transplantation.